Industry
Biotechnology
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Loading...
Open
16.00
Mkt cap
27M
Volume
50K
High
16.44
P/E Ratio
-2.42
52-wk high
32.55
Low
15.64
Div yield
N/A
52-wk low
5.40
Portfolio Pulse from
November 19, 2024 | 2:15 pm
Portfolio Pulse from
November 12, 2024 | 2:15 pm
Portfolio Pulse from
November 07, 2024 | 2:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 4:35 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 1:02 pm
Portfolio Pulse from Avi Kapoor
September 12, 2024 | 9:46 am
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 1:04 pm
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 1:21 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:50 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 1:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.